Scinai Immunotherapeutics LT
13F holders, Q4 2024 (December 31)4holders −1
0new positions
1sold out
$3.34avg. 13F price*
At the end of Q4 2024, 4 institutions reported holding Scinai Immunotherapeutics LT in their 13F filings, down 1 from Q3 2024. 0 opened new positions and 1 sold out. The largest holders were UBS Group AG ($79K), Rhumbline Advisers ($6K) and Morgan Stanley ($853).
- Company
- Scinai Immunotherapeutics LT
- CUSIP
- 09073Q303
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $110 |
All 13F filers, Q3 2024 → Q4 2024: 23,458 shares bought and 32 shares sold, net +23,426 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| UBS Group AG | 0.00% | Add +78193.3% | 23,488 | $79K |
| Rhumbline Advisers | 0.00% | No change | 1,653 | $6K |
| Morgan Stanley | 0.00% | No change | 255 | $853 |
| Credit Agricole S A | 0.00% | No change | 42 | $140 |
"% of holder's portfolio" is SCINAI IMMUNOTHERAPEUTICS LT's weight in each manager's 13F, not the share of Scinai Immunotherapeutics LT the manager owns.